Bayer AG (BAYRY) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Bayer AG (BAYRY) Healthcare & Pipeline Overview

Bayer AG, a prominent life science company, excels in pharmaceuticals, consumer health, and crop science, leveraging innovation to address global health and agricultural challenges while maintaining a strong market presence.

What Is the Investment Thesis for BAYRY?

Bayer AG's investment thesis is anchored in its diversified business model, which spans pharmaceuticals, consumer health, and crop science, providing resilience against market fluctuations. The company has a market capitalization of $55.3B, with a gross margin of 59.3%, indicating strong operational efficiency. Key growth catalysts include ongoing collaborations for drug development, particularly in oncology and women's health, which could enhance its product pipeline and revenue streams. Additionally, Bayer's commitment to sustainability in its Crop Science segment aligns with increasing global demand for sustainable agricultural practices, positioning the company favorably in a rapidly evolving market. However, investors should remain vigilant regarding the potential risks associated with regulatory approvals and patent expirations, which could impact future earnings.

Based on FMP financials and quantitative analysis

BAYRY Key Highlights

Market cap of $55.3B reflects Bayer's strong position in the healthcare sector.

• Gross margin of 59.3% indicates efficient operations compared to industry peers.
• Profit margin of -4.8% highlights ongoing challenges in profitability.
• Beta of 0.84 suggests lower volatility compared to the broader market.
• Dividend yield of 0.30% provides a modest return to shareholders.

Who Are BAYRY's Competitors?

BAYRY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are BAYRY's Key Strengths?

Strong global presence with operations in over 100 countries.

• Diverse portfolio across pharmaceuticals, consumer health, and crop science.
• Robust R&D capabilities driving innovation and product development.
• Established collaborations with leading research institutions.

What Are BAYRY's Weaknesses?

Recent financial performance impacted by litigation and regulatory challenges.

• Dependence on a few key products for a significant portion of revenue.
• Profit margin under pressure from competitive pricing and market dynamics.

What Are the Key Risks for BAYRY?

Financial-distress signal — its Altman Z-Score of 0.98 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-7.5%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Exposure to regulatory challenges affecting product approvals.
• Competition from generic and biosimilar products impacting market share.
• Legal risks associated with ongoing litigation and settlements.
• Fluctuations in currency exchange rates affecting profitability.

What Are the Growth Opportunities for BAYRY?

• Growth opportunity 1: Bayer is focusing on expanding its oncology portfolio through collaborations with leading research institutions like MD Anderson Cancer Center. Bayer's innovative therapies and strong pipeline could capture a substantial share of this market, driving revenue growth in the coming years.
• Growth opportunity 2: The Consumer Health segment is set to benefit from increasing consumer awareness regarding health and wellness.
• Growth opportunity 3: Bayer's Crop Science segment aims to address the growing demand for sustainable agricultural solutions. Bayer's commitment to innovation in crop protection and digital farming solutions will enable it to capture a significant portion of this market, particularly as farmers seek sustainable practices.
• Growth opportunity 4: Bayer's investment in digital health solutions is expected to enhance patient engagement and improve health outcomes. By integrating technology into its healthcare offerings, Bayer can improve patient experiences and drive growth across its pharmaceutical and consumer health segments.
• Bayer's ongoing research and development efforts in this area, particularly in collaboration with institutions like Kyoto University, position it to be a key player in this transformative market, potentially leading to significant revenue growth.

What Opportunities Does BAYRY Have?

• Expansion into emerging markets with growing healthcare needs.
• Increased demand for sustainable agricultural practices and products.
• Growth potential in digital health and telemedicine solutions.

What Threats Does BAYRY Face?

• Intense competition from both established and emerging pharmaceutical companies.
• Regulatory changes and challenges impacting product approvals.
• Patent expirations leading to increased competition from generics.

What Are BAYRY's Competitive Advantages?

• Strong brand recognition in pharmaceuticals and consumer health.
• Extensive R&D capabilities leading to innovative product offerings.
• Diverse product portfolio reducing dependence on any single segment.
• Established partnerships with leading research institutions enhancing innovation.
• Global distribution network ensuring broad market reach.

What Does BAYRY Do?

Bayer Aktiengesellschaft, founded in 1863 and headquartered in Leverkusen, Germany, is a global leader in life sciences, operating through three main segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals segment focuses on prescription products, particularly in cardiology and women's health, offering specialty therapeutics for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment and cell and gene therapies. The Consumer Health segment markets a variety of nonprescription products, including over-the-counter medicines, medical products, and nutritional supplements, addressing diverse health needs such as dermatology, pain management, and digestive health. Bayer's Crop Science segment provides innovative solutions for agriculture, including chemical and biological crop protection products, improved plant traits, and digital farming solutions. The company has established numerous collaborations and partnerships with leading research institutions, such as MD Anderson Cancer Center and the University of Oxford, to drive innovation in drug development. With a workforce of approximately 90,587 employees, Bayer distributes its products through various channels, including wholesalers, pharmacies, supermarkets, and directly to farmers, ensuring a broad geographic reach and strong market positioning.

What Products and Services Does BAYRY Offer?

• Develops and markets prescription pharmaceuticals for various health conditions.
• Offers over-the-counter consumer health products, including pain relief and nutritional supplements.
• Provides crop science solutions, including seeds and crop protection products.
• Engages in research collaborations to innovate new therapies and treatments.
• Distributes products globally through various channels, including pharmacies and supermarkets.
• Focuses on sustainability and innovation in agriculture and healthcare.

How Does BAYRY Make Money?

• Generates revenue through the sale of pharmaceutical products and therapies.
• Markets consumer health products directly to consumers and through retail channels.
• Offers agricultural solutions to farmers, including seeds and crop protection products.
• Engages in strategic partnerships to enhance R&D capabilities and product offerings.
• Utilizes a diversified portfolio to mitigate risks associated with market fluctuations.

What Industry Does BAYRY Operate In?

The drug manufacturing industry is experiencing significant growth, driven by advancements in biotechnology, increasing healthcare expenditures, and a rising global population. Bayer AG operates in a competitive landscape alongside firms like Sandoz Group AG (SDZNY), Otsuka Holdings Co., Ltd. (OTSKY), and Fresenius SE & Co. KGaA (FSNUF). Bayer's diversified portfolio allows it to leverage emerging trends in both healthcare and agriculture, positioning it well for future growth.

Who Are BAYRY's Key Customers?

• Healthcare providers and hospitals seeking innovative therapies.
• Consumers purchasing over-the-counter health products.
• Farmers requiring crop protection and seed solutions.
• Research institutions partnering for drug development.
• Retailers and wholesalers distributing Bayer's products.

Bayer AG (BAYRY) Valuation Context

Valued at $55.3B, BAYRY is classified as a large-cap stock. Relative to its peer group, BAYRY's quantitative score of 51/100 is roughly in line with the peer average of 55/100.

BAYRY Revenue & Earnings Trend

In Q2 FY2026, BAYRY generated $12.61B in top-line revenue, marking a sequential decrease of 20.2%. The company recorded net income of $254.1M, with diluted EPS of $0.06. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, BAYRY averaged $-0.12 in diluted EPS.

Company Profile

Bayer AG operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Leverkusen, DE. The company is led by CEO Bill Anderson. BAYRY has traded publicly since 1996.

Return on equity for Bayer AG stands at -7.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -2.0%, showing how much profit it generates from its asset base. Its free cash flow yield is 5.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.06 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.1%, the inverse of the P/E and a quick read on earnings relative to price.

Bayer AG's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.98 places it in the distress zone, a signal of elevated financial risk.

Bayer AG has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 9.2% above estimates on average.

BAYRY Financials

BAYRY Latest News

BAYRY Analyst Consensus

BAYRY MoonshotScore

Latest Bayer AG Analysis

What Investors Ask About Bayer AG (BAYRY) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources